Soleno Therapeutics (SLNO) Price & Analysis

Compare

924 Followers

SLNO Stock Chart & Stats

$38.57

-$1.55(-3.35%)

At close: Jan 08 4:00 PM EST

$38.57

-$1.55(-3.35%)

Day’s Range― - ―

52-Week Range$32.63 - $90.32

Previous CloseN/A

Volume118.06K

Average Volume (3M)1.45M

Market Cap

$1.99B

Enterprise Value$2.00B

Total Cash (Recent Filing)$305.47M

Total Debt (Recent Filing)$2.69M

Price to Earnings (P/E)117.9

Beta0.47

Next Earnings

May 12, 2026

EPS Estimate

0.67

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.80

Shares Outstanding51,624,386

10 Day Avg. Volume1,581,818

30 Day Avg. Volume1,454,415

Financial Highlights & Ratios

PEG Ratio-1.08

Price to Book (P/B)5.47

Price to Sales (P/S)12.93

P/FCF Ratio52.69

Enterprise Value/Market Cap1.01

Enterprise Value/Revenue10.53

Enterprise Value/Gross Profit10.68

Enterprise Value/Ebitda70.61

Forecast

1Y Price Target

$103.20

Price Target Upside167.57% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering10

EPS Forecast (FY)4.06

Revenue Forecast (FY)$478.81M

Bulls Say, Bears Say

Bulls Say

Commercial AdoptionAnalyst highlights accelerating uptake of VYKAT XR driven by repeat prescribing from key specialists and peer-to-peer influence, supporting continued revenue growth.

Regulatory ExpansionCompany has addressed regulator questions and remains positioned for potential European approval, which would materially expand the market opportunity outside the United States.

Reimbursement ExpansionAnalyst notes widening payer coverage across commercial plans, Medicaid, and Medicare that reduces access barriers and supports broader patient treatment initiation.

Bears Say

Addressable Population LimitsCertain patients with specific heart conditions, gout, or on incompatible medications are unlikely candidates for VYKAT XR, narrowing the treatable population and capping potential uptake.

Safety And DiscontinuationsAnalyst reports treatment discontinuations related to adverse events are occurring and may limit patient retention and reduce long‑term revenue per patient.

Uptake Momentum RiskAnalyst flags slowing new patient starts across successive launch periods, which could weaken future sales momentum despite early revenue strength.

Soleno Therapeutics News

Soleno Therapeutics price target lowered to $100 from $120 at H.C. Wainwright

H.C. Wainwright analyst Raghuram Selvaraju lowered the firm’s price target on Soleno Therapeutics (SLNO) to $100 from $120...

3d ago

SLNO

Biotech Bloodbath Drags Health Care Down as MannKind and Soleno Stocks Sink

The biotech sector took a hit this week despite a recent spike in search activity. The SPDR S&P...

8d ago

IBB

XBI

Soleno Therapeutics price target lowered to $110 from $114 at Wells Fargo

Wells Fargo lowered the firm’s price target on Soleno Therapeutics (SLNO) to $110 from $114 and keeps an...

8d ago

SLNO

Soleno Therapeutics price target lowered to $85 from $120 at TD Cowen

TD Cowen analyst Tyler Van Buren lowered the firm’s price target on Soleno Therapeutics (SLNO) to $85 from...

9d ago

SLNO

Soleno Therapeutics CFO Mackaness to retire, Fulk to succeed

Soleno Therapeutics (SLNO) announced the appointment of Jennifer Fulk as Chief Financial Officer, succeeding James Mackaness, who announced...

9d ago

LLY

SLNO

Soleno Therapeutics reports Q4 EPS 80c vs. ($1.27) last year

Reports Q4 revenue $91.73M, consensus $88.55M. “Our first year as a commercial organization has been an outstanding success,”...

9d ago

SLNO

Soleno Therapeutics’ Risky Bet on VYKAT XR: Commercial, Regulatory, and Funding Hurdles Threaten Path to Profitability

Soleno Therapeutics (SLNO) has disclosed a new risk, in the Sales & Marketing category. Soleno Therapeutics has only...

8d ago

SLNO

Soleno Therapeutics Announces New Chief Financial Officer Appointment

Soleno Therapeutics ( ($SLNO) ) has issued an update. On its February 25, 2026 earnings call, Soleno announced...

9d ago

SLNO

Soleno Therapeutics: Strong Early Vykat XR Traction, Rapid Market Penetration, and Expanding Growth Opportunities Support Buy Rating

Tyler Van Buren, an analyst from TD Cowen, maintained the Buy rating on Soleno Therapeutics. The associated price...

9d ago

SLNO

SLNO Upcoming Earnings Report: What to Expect?

Soleno Therapeutics (SLNO) is scheduled to report 4th quarter earnings on 02/25/2026, after the market closes. Regarding Q4...

12d ago

SLNO

Strategic Investment Fuels Confidence in Soleno Therapeutics’ Growth Outlook and Supports Buy Rating

Analyst Tyler Van Buren from TD Cowen maintained a Buy rating on Soleno Therapeutics and keeping the price...

1M ago

SLNO

Soleno Therapeutics Updates Executive Compensation and Severance Plans

Soleno Therapeutics ( ($SLNO) ) just unveiled an announcement. On January 21, 2026, Soleno Therapeutics’ board, following a...

1M ago

SLNO

Soleno Therapeutics: Strong VYKAT XR Outperformance, Solid Balance Sheet, and Global Growth Optionality Drive Higher Buy-Rated Target

Ram Selvaraju, an analyst from H.C. Wainwright, reiterated the Buy rating on Soleno Therapeutics. The associated price target...

2M ago

SLNO

Soleno Therapeutics price target raised to $120 from $110 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Soleno Therapeutics (SLNO) to $120 from $110 and keeps a...

2M ago

SLNO

SLNO FAQ

What was Soleno Therapeutics Inc’s price range in the past 12 months?

Soleno Therapeutics Inc lowest stock price was $32.63 and its highest was $90.32 in the past 12 months.

What is Soleno Therapeutics Inc’s market cap?

Soleno Therapeutics Inc’s market cap is $1.99B.

When is Soleno Therapeutics Inc’s upcoming earnings report date?

Soleno Therapeutics Inc’s upcoming earnings report date is May 12, 2026 which is in 66 days.

How were Soleno Therapeutics Inc’s earnings last quarter?

Soleno Therapeutics Inc released its earnings results on Feb 25, 2026. The company reported $0.8 earnings per share for the quarter, beating the consensus estimate of $0.711 by $0.089.

Is Soleno Therapeutics Inc overvalued?

According to Wall Street analysts Soleno Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Soleno Therapeutics Inc pay dividends?

Soleno Therapeutics Inc does not currently pay dividends.

What is Soleno Therapeutics Inc’s EPS estimate?

Soleno Therapeutics Inc’s EPS estimate is 0.67.

How many shares outstanding does Soleno Therapeutics Inc have?

Soleno Therapeutics Inc has 51,624,386 shares outstanding.

What happened to Soleno Therapeutics Inc’s price movement after its last earnings report?

Soleno Therapeutics Inc reported an EPS of $0.8 in its last earnings report, beating expectations of $0.711. Following the earnings report the stock price went down -7.12%.

Which hedge fund is a major shareholder of Soleno Therapeutics Inc?

Currently, no hedge funds are holding shares in SLNO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Soleno Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

5.89%

Trailing 12-Months

Asset Growth

70.36%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Soleno Therapeutics Inc

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

Soleno Therapeutics (SLNO) Earnings & Revenues

Historic Earnings Reports

SLNO Earnings Call

Q4 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call communicated a strong commercial launch and material financial progress — meaningful sequential revenue growth (~40% Q/Q), positive operating cash flow and full-year profitability — alongside encouraging commercial metrics (1,250 start forms, 859 active patients, 630 prescribers and coverage of >180M lives). Key near-term risks flagged include EU regulatory uncertainty, anticipated increases in COGS as inventory normalizes, seasonality-driven Q1 gross-to-net effects, elevated SG&A for continued launch investment, and an expected long-term discontinuation range of 15%–20%. On balance, the positive financial and commercial momentum and ample cash runway outweigh the outlined challenges.View all SLNO earnings summaries

SLNO Stock 12 Month Forecast

Average Price Target

$103.20

▲(167.57% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"38":"$38","60":"$60","82":"$82","104":"$104","126":"$126"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":125,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$125.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":103.2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$103.20</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":60,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$60.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[38,60,82,104,126],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,39.06,45.67076923076923,52.28153846153846,58.892307692307696,65.50307692307692,72.11384615384615,78.72461538461539,85.33538461538461,91.94615384615385,98.55692307692308,105.1676923076923,111.77846153846154,118.38923076923078,{"y":125,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,39.06,43.99384615384616,48.92769230769231,53.86153846153846,58.79538461538462,63.72923076923077,68.66307692307691,73.59692307692308,78.53076923076924,83.46461538461539,88.39846153846153,93.3323076923077,98.26615384615384,{"y":103.2,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,39.06,40.67076923076923,42.28153846153846,43.892307692307696,45.503076923076925,47.113846153846154,48.72461538461538,50.33538461538461,51.94615384615385,53.55692307692308,55.167692307692306,56.77846153846154,58.389230769230764,{"y":60,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":48.82,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.26,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.02,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.66,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82.63,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":86,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.22,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60.12,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.16,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.02,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.3,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.32,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.06,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >